InduPro Raises $77M for Oncology Biotech
InduPro raised a $77M Series B for oncology biotech, with strategic participation from major pharma-linked investors.
Biotech funding is selective, but strong oncology platforms are still attracting serious capital.
What happened
InduPro raised a $77M Series B. The Cambridge-based oncology biotech is developing therapeutic approaches in cancer, with participation from venture investors and major pharma-linked backers.
The round stands out because it combines specialist biotech venture capital with strategic interest from large pharmaceutical groups.
Why it matters
Oncology remains one of the most competitive and capital-intensive areas of biotech. Investors are still willing to fund companies that appear to have differentiated science, strong platform potential or strategic relevance to future drug pipelines.
InduPro’s financing suggests that despite a tougher biotech market, high-conviction cancer programmes can still raise meaningful rounds.
The bigger picture
The biotech funding market is not closed. It is more selective. Capital is flowing toward companies with clearer scientific theses, strong syndicates and potential strategic alignment with larger pharmaceutical players.